Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19
Authors
- B. Krämer
- R. Knoll
- L. Bonaguro
- M. ToVinh
- J. Raabe
- R. Astaburuaga-García
- J. Schulte-Schrepping
- K.M. Kaiser
- G.J. Rieke
- J. Bischoff
- M.B. Monin
- C. Hoffmeister
- S. Schlabe
- E. De Domenico
- N. Reusch
- K. Händler
- G. Reynolds
- N. Blüthgen
- G. Hack
- C. Finnemann
- H.D. Nischalke
- C.P. Strassburg
- E. Stephenson
- Y. Su
- L. Gardner
- D. Yuan
- D. Chen
- J. Goldman
- P. Rosenstiel
- S.V. Schmidt
- E. Latz
- K. Hrusovsky
- A.J. Ball
- J.M. Johnson
- P.A. Koenig
- F.I. Schmidt
- M. Haniffa
- J.R. Heath
- B.M. Kümmerer
- V. Keitel
- B. Jensen
- P. Stubbemann
- F. Kurth
- L.E. Sander
- B. Sawitzki
- A.C. Aschenbrenner
- J.L. Schultze
- J. Nattermann
Journal
- Immunity
Citation
- Immunity 54 (11): 2650-2669
Abstract
Longitudinal analyses of the innate immune system, including the earliest time points, are essential to understand the immunopathogenesis and clinical course of coronavirus disease (COVID-19). Here, we performed a detailed characterization of natural killer (NK) cells in 205 patients (403 samples; days 2 to 41 after symptom onset) from four independent cohorts using single-cell transcriptomics and proteomics together with functional studies. We found elevated interferon (IFN)-α plasma levels in early severe COVD-19 alongside increased NK cell expression of IFN-stimulated genes (ISGs) and genes involved in IFN-α signaling, while upregulation of tumor necrosis factor (TNF)-induced genes was observed in moderate diseases. NK cells exert anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) activity but are functionally impaired in severe COVID-19. Further, NK cell dysfunction may be relevant for the development of fibrotic lung disease in severe COVID-19, as NK cells exhibited impaired anti-fibrotic activity. Our study indicates preferential IFN-α and TNF responses in severe and moderate COVID-19, respectively, and associates a prolonged IFN-α-induced NK cell response with poorer disease outcome.